Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Synaptotagmin, GAP1, and centaurin-alpha inositol phosphate–binding domains refer to a specialized group of protein domains—specifically the C2B domain of Synaptotagmin and the Pleckstrin Homology (PH) domains of GAP1 (RASA3) and Centaurin-alpha (ADAP1)—that function as high-affinity receptors for the second messenger inositol 1,3,4,5-tetraphosphate (Ins(1,3,4,5)P4). These domains play a pivotal role in cellular signaling by translating changes in inositol phosphate levels into downstream physiological responses. In the nervous system, Synaptotagmin-1 uses its C2B domain to bind IP4, which can competitively inhibit calcium-dependent vesicle fusion and neurotransmitter release. In other tissues, the PH domains of GAP1 and Centaurin-alpha mediate their recruitment to the plasma membrane, where they act as GTPase-activating proteins (GAPs) for Ras and Arf, respectively, thereby regulating cell growth, differentiation, and membrane trafficking. While no FDA-approved drugs currently target these domains directly, they are of significant interest in the development of therapies for neurodegenerative diseases, cancer, and thrombosis, where dysregulation of inositol phosphate signaling is implicated.
Competitive binding to inositol phosphate-binding sites, modulation of GTPase activity, and regulation of calcium-dependent vesicle fusion.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Synaptotagmin, GAP1, and centaurin-alpha inositol phosphate–binding domains (IP4-binding domains).